How ketamine trials are providing a blueprint for suicidal ideation research
NIMH’s Dr Elizabeth Ballard discusses how ketamine has laid the groundwork for a new paradigm of suicide research.
Healthcare
Competition grows to be the next disease-modifying therapy for Alzheimer’s disease
There is a number of DMT therapies for AD that are at the last stages...
New blood test could improve prostate cancer screening
A new novel blood test called the Stockholm3test could boost the prostate cancer screening process...
Alzheimer’s disease clinical trials not significantly impacted by the Covid-19 pandemic
Alzheimer’s disease trials have seen minor disruptions due to the Covid-19 pandemic, with only a...
FDA approves first trial investigating CRISPR gene editing as HIV cure
A new paradigm for HIV treatment is on the horizon as FDA gives nod for...
Childhood type 2 diabetes on the rise in England
According to GlobalData, type 2 diabetes in young people in England is set to increase in 2028, though initiatives such as the LGA's are promising.
Algae proteins and optogenetics: a vision of the future
The vision of a completely blind man has been partially restored using light-sensing proteins found in algae.
ACTIV-3: AZ Covid-19 antibody cocktail trial set to complete enrolment by end of month
A large study evaluating AstraZeneca’s Covid-19 monoclonal antibody will soon have data on its use in hospitalised patients.
OpRegen: tackling the leading cause of blindness with cell replacement
Lineage Cell Therapeutics has been able to reverse retinal damage caused by dry AMD in a Phase I/II trial with its lead candidate OpRegen.
Forget Covid: Brexit is still the biggest threat to UK healthcare
Survey reveals for more than half of European healthcare industry professionals Brexit will wreak greater havoc than the pandemic, writes Giacomo Lee.
Why 5G is the MVP of the healthcare tech revolution
The healthcare industry stands to benefit enormously from the adoption of 5G tech, reports Giacomo Lee.
